Open AccessAssessing the Clinical Improvement in Patients with COVID-19 using Lopinavir-Ritonavir: A Systematic Review
Author(s) -
Rania Magadmi
Publication year - 2021
Publication title -
journal of pharmaceutical research international
Language(s) - English
Resource type - Journals
ISSN - 2456-9119
DOI - 10.9734/jpri/2021/v33i44a32637
Subject(s) - lopinavir , ritonavir , lopinavir/ritonavir , covid-19 , medicine , pandemic , intensive care medicine , pharmacology , virology , disease , viral load , human immunodeficiency virus (hiv) , antiretroviral therapy , infectious disease (medical specialty)
Aims: Globally the focus is towards finding an effective treatment for COVID-19 patients in order to suppress the spread of this pandemic disease. An antiviral combination of lopinavir-ritonavir is considered to be effective in treating COVID-19 patients. Therefore, the present study aims to assess the clinical improvements of lopinavir-ritonavir in COVID-19 patients.
Study Design: a systematic review study was conducted and articles published since December 2019 were included. The statistical analysis of quantitative data was performed using Review Manager (RevMan) to generate forest plots.
Results: The study showed that there was no significant difference in COVID-19 patients treated with lopinavir-ritonavir or in combination with anti-viral therapy or other conventional methods. Conclusion: the use of lopinavir-ritonavir resulted in greater adverse consequences among COVID-19 patients. It further recommends conducting meta-analysis studies with a greater number of studies to highlight the clinical improvement associated with the use of Lopinavir-ritonavir.